Alpine Immune Sciences, Inc. (ALPN) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Seattle, WA, 미국. 현재 CEO는 Mitchell H. Gold.
ALPN 을(를) 보유 IPO 날짜 2015-06-17, 142 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $4.46B.
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to treat cancer, autoimmune disorders, and inflammatory diseases. The company's pipeline includes ALPN-101, an ICOS/CD28 antagonist for autoimmune and inflammatory conditions; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for cancer treatment; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated diseases. Alpine has established strategic collaborations with AbbVie Ireland for ALPN-101 development and with Adaptimmune Therapeutics for next-generation SPEAR T cell products. Founded in 2007 and headquartered in Seattle, Washington, the company leverages its immunotherapy expertise to address significant unmet medical needs across multiple therapeutic areas.
